Treehill Partners

Stem cells
#Cell therapy #Kidswell Bio #Regenerative Medicine #Stem cells #Treehill Partners

Partners launch new regenerative medicine company

Kidswell Bio and Treehill Partners have announced the creation of a new US based regenerative medicine company, Kidswell USA.   The companies say Kidswell USA will be formed for the purpose of accelerating the development of Kidswell’s cell therapy pipeline, currently targeting cerebral palsy (CP) as a lead… Read More

#News

Doctor points at child's brain scan
#Biosimilars #Cerebral Palsy #Thermo Fisher Scientific #Treehill Partners

New company to advance cerebral palsy therapy 

A new regenerative medicine company is set to develop a novel cell and gene therapy targeting paediatric cerebral palsy (CP).  Kidswell USA has been formed by a partnership between biosimilars and cell therapies company Kidswell Bio Corporation and corporate development advisor Treehill Partners.  In the new company, Kidswell and Treehill aim to advance their… Read More

#News

#Drug development #Investment #Life sciences #Treehill Partners #US government

Expert opinion on life sciences in a Trump/RFK era

Max Baumann, Co-Founder and Head of Execution of Treehill Partners, discusses what investors, drug developers, and the rest of the life science sector can do to prepare for the Trump/RFK era. The arrival of a new US administration generates significant industry-wide speculation and anticipation regarding new policies and agendas that may… Read More

#Business & Investment #Exclusive Content #Opinion

2024 predictions, road forward
#2024 predictions #Funding #Investment #Life science #Pharma Collective #Treehill Partners

2024 predictions: Thought leaders on finance and investment 

DDW’s Megan Thomas spoke to experts from the drug discovery industry about their predictions on what 2024 holds for our sector. This is part of a series of predictions based on different themes, which include insight into the future for cancer and immunotherapy, as well as AI, ML and automation. Read More

#Exclusive Content #Trends & Analysis